FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087095969> ?p ?o ?g. }

• W2087095969 endingPage "439" @default.
• W2087095969 startingPage "433" @default.
• W2087095969 abstract "Vascular endothelial growth factor receptor 2 (VEGFR2) is an essential factor in tumor angiogenesis and in the growth of pancreatic cancer. Immunotherapy using epitope peptide for VEGFR2 (VEGFR2‐169) that we identified previously is expected to improve the clinical outcome. Therefore, a phase I clinical trial combining of VEGFR2‐169 with gemcitabine was conducted for patients with advanced pancreatic cancer. Patients with metastatic and unresectable pancreatic cancer were eligible for the trial. Gemcitabine was administered at a dose of 1000 mg/m 2 on days 1, 8, and 15 in a 28‐day cycle. The VEGFR2‐169 peptide was subcutaneously injected weekly in a dose‐escalation manner (doses of 0.5, 1, and 2 mg/body, six patients/one cohort). Safety and immunological parameters were assessed. No severe adverse effect of grade 4 or higher was observed. Of the 18 patients who completed at least one course of the treatment, 15 (83%) developed immunological reactions at the injection sites. Specific cytotoxic T lymphocytes (CTL) reacting to the VEGFR2‐169 peptide were induced in 11 (61%) of the 18 patients. The disease control rate was 67%, and the median overall survival time was 8.7 months. This combination therapy for pancreatic cancer patients was tolerable at all doses. Peptide‐specific CTL could be induced by the VEGFR2‐169 peptide vaccine at a high rate, even in combination with gemcitabine. From an immunological point of view, the optimal dose for further clinical trials might be 2 mg/body or higher. This trial was registered with ClinicalTrial.gov (no. NCT 00622622). ( Cancer Sci 2009)" @default.
• W2087095969 created "2016-06-24" @default.
• W2087095969 creator A5000823360 @default.
• W2087095969 creator A5005209390 @default.
• W2087095969 creator A5021237761 @default.
• W2087095969 creator A5040216764 @default.
• W2087095969 creator A5051950705 @default.
• W2087095969 creator A5058284228 @default.
• W2087095969 creator A5073275097 @default.
• W2087095969 creator A5079171795 @default.
• W2087095969 date "2010-01-29" @default.
• W2087095969 modified "2023-10-17" @default.
• W2087095969 title "Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer" @default.
• W2087095969 cites W1931508686 @default.
• W2087095969 cites W1965402114 @default.
• W2087095969 cites W1965542961 @default.
• W2087095969 cites W1976905678 @default.
• W2087095969 cites W1985043086 @default.
• W2087095969 cites W1992699637 @default.
• W2087095969 cites W2004956320 @default.
• W2087095969 cites W2009427112 @default.
• W2087095969 cites W2014133561 @default.
• W2087095969 cites W2027451548 @default.
• W2087095969 cites W2043103956 @default.
• W2087095969 cites W2051940153 @default.
• W2087095969 cites W2055479791 @default.
• W2087095969 cites W2083613364 @default.
• W2087095969 cites W2084844081 @default.
• W2087095969 cites W2085034745 @default.
• W2087095969 cites W2091436536 @default.
• W2087095969 cites W2097642908 @default.
• W2087095969 cites W2100690235 @default.
• W2087095969 cites W2101465269 @default.
• W2087095969 cites W2111415894 @default.
• W2087095969 cites W2117105709 @default.
• W2087095969 cites W2123344367 @default.
• W2087095969 cites W2124757685 @default.
• W2087095969 cites W2128562119 @default.
• W2087095969 cites W2129056290 @default.
• W2087095969 cites W2135352785 @default.
• W2087095969 cites W2144248058 @default.
• W2087095969 cites W2154574630 @default.
• W2087095969 cites W2156079175 @default.
• W2087095969 cites W2158134441 @default.
• W2087095969 cites W2160081417 @default.
• W2087095969 cites W2162651519 @default.
• W2087095969 cites W2242441950 @default.
• W2087095969 cites W4252851641 @default.
• W2087095969 doi "https://doi.org/10.1111/j.1349-7006.2009.01416.x" @default.
• W2087095969 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19930156" @default.
• W2087095969 hasPublicationYear "2010" @default.
• W2087095969 type Work @default.
• W2087095969 sameAs 2087095969 @default.
• W2087095969 citedByCount "99" @default.
• W2087095969 countsByYear W20870959692012 @default.
• W2087095969 countsByYear W20870959692013 @default.
• W2087095969 countsByYear W20870959692014 @default.
• W2087095969 countsByYear W20870959692015 @default.
• W2087095969 countsByYear W20870959692016 @default.
• W2087095969 countsByYear W20870959692017 @default.
• W2087095969 countsByYear W20870959692018 @default.
• W2087095969 countsByYear W20870959692019 @default.
• W2087095969 countsByYear W20870959692020 @default.
• W2087095969 countsByYear W20870959692021 @default.
• W2087095969 countsByYear W20870959692022 @default.
• W2087095969 countsByYear W20870959692023 @default.
• W2087095969 crossrefType "journal-article" @default.
• W2087095969 hasAuthorship W2087095969A5000823360 @default.
• W2087095969 hasAuthorship W2087095969A5005209390 @default.
• W2087095969 hasAuthorship W2087095969A5021237761 @default.
• W2087095969 hasAuthorship W2087095969A5040216764 @default.
• W2087095969 hasAuthorship W2087095969A5051950705 @default.
• W2087095969 hasAuthorship W2087095969A5058284228 @default.
• W2087095969 hasAuthorship W2087095969A5073275097 @default.
• W2087095969 hasAuthorship W2087095969A5079171795 @default.
• W2087095969 hasConcept C121608353 @default.
• W2087095969 hasConcept C126322002 @default.
• W2087095969 hasConcept C143998085 @default.
• W2087095969 hasConcept C147483822 @default.
• W2087095969 hasConcept C167734588 @default.
• W2087095969 hasConcept C195616568 @default.
• W2087095969 hasConcept C197934379 @default.
• W2087095969 hasConcept C203014093 @default.
• W2087095969 hasConcept C2776694085 @default.
• W2087095969 hasConcept C2776789287 @default.
• W2087095969 hasConcept C2777025900 @default.
• W2087095969 hasConcept C2778822529 @default.
• W2087095969 hasConcept C2780210213 @default.
• W2087095969 hasConcept C2780258809 @default.
• W2087095969 hasConcept C2780394083 @default.
• W2087095969 hasConcept C31760486 @default.
• W2087095969 hasConcept C535046627 @default.
• W2087095969 hasConcept C71924100 @default.
• W2087095969 hasConcept C90924648 @default.
• W2087095969 hasConceptScore W2087095969C121608353 @default.
• W2087095969 hasConceptScore W2087095969C126322002 @default.
• W2087095969 hasConceptScore W2087095969C143998085 @default.
• W2087095969 hasConceptScore W2087095969C147483822 @default.

• next